R-3-hydroxybutyrate binding proteins (bhbbps) and their use for ketone monitoring

R-3-hydroxybutyrate binding proteins are used to develop a continuous ketone monitoring system, addressing the limitations of existing technologies by enabling accurate and continuous measurement of BHB levels without requiring soluble cofactors, thus improving the management of diabetic ketoacidosis.

WO2024249832A1PCT designated stage expired Publication Date: 2024-12-05THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/031965
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current ketone monitoring systems for diabetic ketoacidosis lack accurate and continuous measurement of R-3-hydroxybutyrate (BHB) levels due to the limited availability of molecular recognition molecules that require soluble cofactors, making them unsuitable for continuous monitoring.

Method used

Development of R-3-hydroxybutyrate binding proteins (BHBBPs) with at least 80% sequence identity to specific sequences, which are used to create recombinant plasmids, expressed in host cells, and employed in methods for determining BHB concentrations using fluorescent or redox probes, immobilized electrodes, and biosensors for continuous ketone monitoring.

Benefits of technology

Enables accurate and continuous monitoring of BHB levels without the need for soluble cofactors, providing dynamic information for managing and preventing diabetic ketoacidosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000046
    Figure 000046
  • Figure 000047
    Figure 000047
  • Figure 000048
    Figure 000048
Patent Text Reader

Abstract

Compositions, devices, kits, and methods are disclosed for assaying R-3-hydroxybutyrate (BHB) with R-3-hydroxybutyrate binding protein (BHBBP). BHBBPs are derived from several microorganisms to bind BHB specifically, and methods to prepare BHBBPs are disclosed. Methods of determining the concentration BHB in a sample based on fluorometry and electrochemically are also disclosed. Methods and devices to monitor BHB using BHBBP modified electrodes are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

R-3-HYDROXYBUTYRATE BINDING PROTEINs (BHBBPs) AND THEIR USE FOR KETONE MONITORINGINCORPORATION OF SEQUENCE LISTING

[0001] An official copy of the Sequence Listing is submitted electronically via Patent Center as a Sequence Listing with a file named 613802SEQLIST.xml created on May 30, 2024, having a size of 28 kb and is filed concurrently with the specification. The Sequence Listing contained in this document is part of the specification and is herein incorporated by reference in its entirety7.CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 505,576, filed June 1, 2023, the contents of each of which are hereby7incorporated by reference in their entirety7.BACKGROUND

[0003] Diabetic ketoacidosis (DKA) is a life-threatening complication which can occur in individuals with insulin deficiency. It occurs predominantly in Type 1 diabetic patients but is also observed with Type 2 or gestational diabetes. DKA arises from the lack of insulin and other regulatory7hormones such as glucagon and cortisol, which leads to hyperglycemia and accumulation of ketones in blood [1-3], In the case of low glucose uptake, fatty acids are utilized as an energy7source instead of carbohydrates which can lead to ketosis. In normal metabolism, fatty acids are oxidized to produce acetyl CoA, which is shuttled to the citric acid (Krebs) cycle.

[0004] With insulin deficiency, acety l CoA is produced which generates excess quantities of ketone bodies R-3-hydroxybutyrate (PubChem CID 92135. major synonyms are D- 3 -hydroxy butyrate, D-P-hydroxybutyrate, 3-D-hydroxybutyrate, R-P-hydroxybutyrate, R-3-hydroxybutyrate, 3-R-hydroxybutyrate, abbreviated BHB in this invention) and acetoacetate which are then further processed into acetone. The American Diabetes Association (ADA) has advised that continuous blood ketone testing methods to quantify BHB are desirable for diagnosis and monitoring of ketoacidosis. Ketoacidosis occurs when ketone bodies are produced faster than metabolic breakdown [4, 5], Euglycemic DKA has been identified as a potential morbidity7in diabetic patients who take sodium-glucose co-transporter 2 (SGLT-2) inhibitor [6-8], SGLT-2 inhibitors block the absorption of glucose from urine which returns it to the bloodstream during filtration by7the kidneys. By blocking SGLT-2, these medicines cause more glucose to beeliminated in the urine, lowering the blood glucose level with an insulin independent mechanism. Patients treated with SGLT-2 inhibitors may be at higher risk for unrecognized DKA due to increased urinary glucose excretion (in the range of 50 to 100 g / day), resulting in lower blood glucose levels than would be expected in the onset of DKA [9] . In clinical practice, rare but serious DKA have been reported in ty pe 2 diabetes patients treated with SGLT-2 inhibitors and more commonly (absolute risk increase -10% per year in type 1 diabetes). Thus, ketone sensing technologies are receiving greater attention to prevent or improve outcomes of DKA.

[0005] In DKA, BHB is the predominant metabolite (BHB 78%, acetoacetate 20%, acetone 2%)

[0010] , At present, the measurement of ketone bodies is performed using blood or urine samples. For BHB. blood or interstitial fluid (ISF) are considered better testing matrices, because urine does not equate to the plasma ketone concentration [2], A commonly used rule for interpreting blood ketone levels is that normal levels of BHB can be defined as <0.6 mM, ketosis can be defined as levels of 0.6-1.5 mM, hyperketonemia can be defined as levels of 1.5 -3.0 mM, and ketoacidosis can be defined as levels more than 3.0 mM [1 1 J. However, disposable, single-use sensor strips for blood ketone levels which are currently on the market can only offer a snapshot that reflects ketonemia during a specific point in time. Precise dynamic information of blood ketone concentration and, “ketone variability’' is expected to manage and prevent DKA in the diabetic patients

[0012] . which can be achieved through the development of a continuous ketone monitoring system (CKM system).

[0006] In summary7, the main challenge faced currently with respect to continuous ketone monitoring (CKM) is the limited availability7of molecular recognition molecules for BHB. At present, only NAD-dependent dehydrogenases that require soluble NAD+ in the reaction are available, which are largely unsuitable for continuous BHB monitoring, outside of a few exemplary applications. To achieve CKM with improved accuracy and longevity7, the development of new molecular recognition molecules for BHB that can operate without soluble cofactors is necessary7.

[0007] It is in an effort to address the above limitations that the following invention has been developed.BRIEF SUMMARY

[0008] An embodiment is a R-3-hydroxybutyrate binding protein (BHBBP) comprising a sequence having at least 80% sequence identity to any one of SEQ ID NOs: 1-3 or 11- 14.

[0009] An embodiment is a recombinant plasmid comprising a promoter operably linked to a nucleotide sequence encoding an BHBBP as described herein, and prepared by inserting the nucleotide sequence into an expression vector.

[0010] An embodiment is a method of producing recombinant BHBBP. said method comprising:

[0011] i) introducing a recombinant plasmid as described herein into a host cell; and

[0012] ii) expressing the BHBBP.

[0013] An embodiment is a method of determining the concentration of R-3- hydroxybutyrate (BHB) in a sample, the method comprising the steps of:

[0014] i) contacting the sample with a BHBBP, or a BHBBP having a fluorescent probe bound thereto, as described herein;

[0015] ii) contacting the BHBBP with an excitation light;

[0016] iii) measuring the intensity of light emitted from the BHBBP; and

[0017] iv) determining the BHB concentration based on the measurement obtained in step in).

[0018] An embodiment is a method of determining the concentration of R-3- hydroxybutyrate (BHB) in a sample, the method comprising the steps of:

[0019] i) contacting the sample with a BHBBP having a redox probe bound thereto, as described herein;

[0020] ii) applying an alternating potential to the sample, said alternating potential comprising a high potential and a low potential;

[0021] iii) measuring a current in the sample while either the high potential or the low potential is applied; and

[0022] iv) determining the BHB concentration based on the measurement obtained in step in).

[0023] An embodiment is a binding protein immobilized electrode comprising a BHBBP as described herein, immobilized on an electrode.

[0024] An embodiment is a biosensor for assaying BHB concentration comprising the binding protein immobilized electrode as a working electrode.

[0025] An embodiment is a continuous ketone monitoring system, comprising:

[0026] i) a BHBBP, binding protein immobilized electrode, or biosensor as described herein; and ii) a) a light source and a light detection means, or

[0027] b) a means for applying voltage across a sample, and a means for detecting current.BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

[0028] Having thus described the invention in general terms, reference will now be made to the accompanying drawings, which are not necessarily draw n to scale.

[0029] Figure 1A illustrates the oxidation reaction catalyzed by (R)-3-hydroxybutyrate dehydrogenase (BHBDh).

[0030] Figure IB is a schematic depiction of the structural change periplasmic binding proteins (PBPs) undergo when they bind or unbind with ligand, along with a schematic depicting how PBPs have been used in biosensors.

[0031] Figures 2A-2F illustrate putative amino acid sequences of BHBBPs derived from certain organisms (Figures 2A-2C), and the structural genes of these sequences (Figures 2D-2F, respectively).

[0032] Figure 3 illustrates expression vectors subcloned with structural genes of BHBBPs derived from T. thermophilus (left), P. lemoignei (center), and E. melilotl (right), based on pET28a with signal peptide and 6xHis on N and C termini (for T. thermophilus and P. lemoignei), or pET22b with signal peptide removed, pelB fused at the N-terminus, and 6xHis on C-terminus (for E. meliloii).

[0033] Figure 4A illustrates recombinant production and purification conditions of putative BHBBP derived from T. thermophilus. Figure 4B illustrates results of the purification.

[0034] Figure 5 illustrates SDS-PAGE of putative BHBBP derived from T. themophilus after affinity chromatography.

[0035] Figure 6 illustrates Tt.2 BHBBP autofluorescence-based BHB measurement.

[0036] Figures 7A-7B illustrate the use of Tt.2 BHBBP and EDC24 BHBBP, respectively, for autofluorescence-based, chiral BHB quantification from -15-2222 nM with a reference cuvette.

[0037] Figure 8 illustrates the purification of Tt.2 and EDC24 BHBBPs.

[0038] Figure 9 illustrates Tt.2 fluorescence titration experiments.

[0039] Figure 10 illustrates EDC24 fluorescence titration experiments.

[0040] Figure 11 illustrates Tt.2 isothermal calorimetry investigations of BHB binding.

[0041] Figure 12 illustrates control experiments for isothermal calorimetry' investigations of Tt.2 toward non-target molecules.

[0042] Figure 13 illustrates the results of differential scanning fluorimetry with Tt.2 and EDC24.

[0043] Figure 14 illustrates the method for preparation of a PES-modified Tt.2BHBBP immobilized Au disk electrode, and the method of use thereof.

[0044] Figure 15 illustrates raw data from IPA measurements using the Tt.2BHBBP electrode.

[0045] Figure 16 illustrates BHB dependent oxidation current change from IPA measurement in buffer solution.

[0046] Figure 17 illustrates BHB dependent reduction cunent change from IPA measurement in buffer solution.

[0047] Figure 18 illustrates calibration curves of IPA measurement of BHB with PES- Tt.2BHBBP electrode in buffer solution.

[0048] Figure 19 illustrates BHB dependent oxidation cunent change from IPA measurement in artificial ISF.

[0049] Figure 20 illustrates BHB dependent reduction cunent change from IPA measurement in artificial ISF.

[0050] Figure 21 illustrates calibration curves of IPA measurement of BHB with PES- TI.2BHBBP electrode in artificial ISF.

[0051] Figure 22 illustrates the preparation of PES-TI.2BHBBP immobilized of gold wired electrode.

[0052] Figure 23 illustrates cyclic voltammograms of gold wire and disk (rod) electrodes with PES modified TI.2BHBBP.

[0053] Figure 24 illustrates IPA measurement using gold wire electrodes with PES modified Tt.2BHBBP.

[0054] Figure 25 illustrates oxidation current of the sensor with gold wire electrode.

[0055] Figure 26 illustrates reduction current of the sensor with gold wire electrode.

[0056] Figure 27 illustrates the calibration curves for BHB using PES modified TI.2BHBBP immobilized gold wire electrodes with IPA.

[0057] Figures 28A-28D illustrate additional putative amino acid sequences of BHBBPs derived from certain organisms (EDC37, EDC10. NovoS, and BMA2936, respectively).

[0058] Figure 29A-29D illustrate additional structural DNA genes of BHBBPs derived from certain organisms for the amino acid sequences represented in Figures 28A-28D. The genes were synthesized for recombinant production of the proteins.

[0059] Figures 30A-30D illustrate the use of Tt.2, EDC37, EDC24, and NovoS BHBBPs, respectively, for intrinsic fluorescence based, chiral BHB quantification across various concentration ranges.

[0060] Figures 31A-31D illustrate the binding of EDC24. EDC10, BMA2936, and NovoS BHBBPs to BHB via thermal shift assay with differential scanning fluorimetry.

[0061] Figure 32 illustrates the layout of wire sensor using NovoS BHBBP on gold working electrode (WE), and counter electrode (CE) with an Ag / AgCl reference electrode. The working electrode has NovoS immobilized using NTA self assembled monolayer via nickel chelating interaction. Amine reactive phenazine ethosulfate is then conjugated to the NovoS binding protein.

[0062] Figure 33 illustrates the results of square wave voltammetry analyses of arPES modified NovoS protein on gold wire electrodes. After showing the steady state peak current in the absence of P-hydroxybutyrate, the delta peak current was measured over time as the sensor response. The sensor signal increased immediately after the addition of 5 and 10 uM -hydroxybutyrate (final concentration).

[0063] Figure 34 illustrates the calibration curve of P-hydroxybutyrate using NovoS binding protein on gold wire electrode based on square wave voltammetry measurements.DETAILED DESCRIPTION

[0064] The presently disclosed subject matter will now be described more fully hereinafter. However, many modifications and other embodiments of the presently disclosed subject matter set forth herein will come to mind to one skilled in the art to which the presently disclosed subject matter pertains having the benefit of the teachings presented in the foregoing descriptions. Therefore, it is to be understood that the presently disclosed subject matter is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. In other words, the subject matter described herein covers all alternatives, modifications, and equivalents. In the event that one or more of the incorporated literature, patents, and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques,or the like, this application controls. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in this field. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

[0065] The term “subject” refers to a mammal (e.g., a human) in need of detection or quantification of an analyte, or target substance. The subject may include dogs, cats, pigs, cows, sheep, goats, horses, rats, mice, non-human mammals, and humans. The term “subject” does not necessarily exclude an individual that is healthy in all respects and does not have or show signs of elevated or lowered target substance. In embodiments, the sample is a biological sample.

[0066] Compositions or methods “comprising” or “including” one or more recited elements may include other elements not specifically recited. For example, a composition that “comprises” or “includes” a protein may contain the protein alone or in combination with other ingredients.

[0067] Designation of a range of values includes all integers, tenths, and hundredths within or defining the range, and all subranges defined by integers within the range.

[0068] The term “zn vivo” refers to natural environments (e.g., a cell or organism or body) and to processes or reactions that occur within a natural environment.

[0069] “Sequence identity” or “identity” in the context of two polynucleotides or polypeptide sequences refers to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have “sequence similarity” or “similarity.” Means for making this adjustment are well known to those of skill in the art.Typically, this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a scorebetween zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC / GENE (Intelligenetics, Mountain View, California).

[0070] ‘’Percentage of sequence identity’’ refers to the value determined by comparing two optimally aligned sequences (greatest number of perfectly matched residues) over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity. Unless otherwise specified (e.g., the shorter sequence includes a linked heterologous sequence), the comparison window is the full length of the shorter of the two sequences being compared. In some embodiments, the percentage of sequence identity is calculated including any signal peptides which may be present in the pair of proteins. In other embodiments, the sequence identity is calculated by excluding any signal peptides which may be present in the pair of proteins.

[0071] A “promoter’’ is a regulatory region of DNA usually comprising a TATA box capable of directing RNA polymerase II to initiate RNA synthesis at the appropriate transcription initiation site for a particular polynucleotide sequence. A promoter may additionally comprise other regions which influence the transcription initiation rate. The promoter sequences disclosed herein modulate transcription of an operably linked polynucleotide. Examples of promoters can be found, for example, in WO 2013 / 176772, herein incorporated by reference in its entirety for all purposes.

[0072] “Operable linkage” or being “operably linked” includes juxtaposition of two or more components (e.g., a regulatory' sequence, such as a promoter, and another sequence element) such that both components function normally and allow the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components. For example, a promoter can be operably linked to a coding sequence if the promoter controls the level of transcription of the coding sequence in response to the presence or absence of one or more transcriptional regulatory factors. Operable linkage can include such sequences being contiguous witheach other or acting in trans (e.g., a regulatory sequence can act at a distance to control transcription of the coding sequence).

[0073] Unless otherwise stated, sequence identity / similarity values refer to the value obtained using GAP Version 10 using the following parameters: % identity and % similarity7for a nucleotide sequence using GAP Weight of 50 and Length Weight of 3, and the nwsgapdna.cmp scoring matrix; % identity and % similarity for an amino acid sequence using GAP Weight of 8 and Length Weight of 2. and the BLOSUM62 scoring matrix; or any equivalent program thereof. “Equivalent program” includes any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by GAP Version 10.

[0074] Unless otherwise apparent from the context, the term '‘about” encompasses values within a standard margin of error of measurement (e.g., SEM) of a stated value or variations ± 0.5%, 1%, 5%, or 10% from a specified value.

[0075] The singular forms of the articles “a.” “an.” and “the” include plural references unless the context clearly dictates otherwise.

[0076] Statistically significant means p <0.05.

[0077] An embodiment is a R-3-hydroxybutyrate binding protein (BHBBP) comprising a sequence having at least 70% sequence identity to any one of SEQ ID NOs: 1-3 or 11- 14. In an embodiment, the BHBBP comprises a sequence having at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%. at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to any one of SEQ ID NOs:l-3 or 11-14.

[0078] In an embodiment, the BHBBP comprises a sequence having at least 70% sequence identity but less than 100% sequence identity to any one of SEQ ID NOs: 1-3 or 11-14. In an embodiment, the BHBBP comprises a sequence having at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%. at least 89%. at least 90%. at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%,at least 98%, at least 99%, or at least 99.5%, but less than 100% sequence identity' to any one of SEQ ID NOs: l-3 or 11-14.

[0079] In an embodiment, the BHBBP further comprises a fluorescent probe bound thereto.

[0080] In an embodiment, the BHBBP further comprises a redox probe bound thereto. In an embodiment, the redox probe is selected from the group consisting of phenazine ethosulphate, an osmium complex, a ruthenium complex, ferrocene, methylene blue, and heme.

[0081] An embodiment is a recombinant plasmid comprising a promoter operably linked to a nucleotide sequence encoding an BHBBP as described herein, and prepared by inserting the nucleotide sequence into an expression vector.

[0082] In an embodiment, the nucleotide sequence is any one of SEQ ID NOs:4-6 or 15- 18.

[0083] In an embodiment, the expression vector is a pET vector. In an embodiment, the expression vector is a pET28a(+) vector, a pET30 vector, or a pET22b(+) vector.

[0084] An embodiment is a method of producing recombinant BHBBP, said method comprising:

[0085] i) introducing a recombinant plasmid as described herein into a host cell; and

[0086] ii) expressing the BHBBP.

[0087] In an embodiment, the host cell is an E. coll cell, a yeast cell, a mammalian cell, or a plant cell.

[0088] An embodiment is a method of determining the concentration of R-3- hydroxybutyrate (BHB) in a sample, the method comprising the steps of:

[0089] i) contacting the sample with a BHBBP, or a BHBBP having a fluorescent probe bound thereto, as described herein;

[0090] ii) contacting the BHBBP with an excitation light;

[0091] iii) measuring the intensity of light emitted from the BHBBP; and

[0092] iv) determining the BHB concentration based on the measurement obtained in step in).

[0093] In an embodiment, the excitation light has a wavelength of 250-1000 nm. In an embodiment, the excitation light has a wavelength of 280-310 nm. In an embodiment, the excitation light has a wavelength of 295 nm.

[0094] In an embodiment, the light emitted has a wavelength of 200-1000 nm. In an embodiment, the light emitted has a wavelength of 310-350 nm. In an embodiment, thelight emitted has a wavelength of 320-340 nm. In an embodiment, the light emitted has a wavelength of 329 nm.

[0095] In an embodiment, the measurement is a continuous measurement. In an embodiment, the measurement is performed for a period of time ranging from 30 seconds to 7 days. In an embodiment, the period of time is at least, at most, or about 30 seconds. 1 minute, 2 minutes. 3 minutes, 4 minutes, 5 minutes. 10 minutes, 20 minutes. 30 minutes, 40 minutes. 50 minutes. 1 hour. 2 hours, 4 hours. 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 20 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days, or within a range defined by any two of these values.

[0096] In an embodiment, the sample comprises a buffer. In an embodiment, the buffer is potassium phosphate buffer (PPB). In an embodiment, the buffer concentration is 10- lOOO mM PPB.

[0097] In an embodiment, the sample comprises lx phosphate buffered saline (lx PBS). In an embodiment, lx PBS comprises about 137 mM NaCl, about 2.7 mM KC1, about 10 mM NaH2PO4. and about 1.8 mM K2HPO4.

[0098] In an embodiment, the sample comprises whole blood, serum, interstitial fluid (ISF), sweat, or saliva. In an embodiment, the interstitial fluid is artificial interstitial fluid (alSF). In an embodiment, the alSF comprises about 123 mM NaCl, about 3.5 mM KC1, about 2.5 mM CaCh, about 0.7 mM MgCh, about 1.5 mM NaFbPC , and about 10 mM HEPES.

[0099] In an embodiment, the sample comprises ISF.

[0100] An embodiment is a method of determining the concentration of R-3- hydroxybutyrate (BHB) in a sample, the method comprising the steps of:

[0101] i) contacting the sample with a BHBBP having a redox probe bound thereto, as described herein;

[0102] ii) applying an alternating potential to the sample, said alternating potential comprising a high potential and a low potential;

[0103] iii) measuring a current in the sample while either the high potential or the low potential is applied; and

[0104] iv) determining the BHB concentration based on the measurement obtained in step hi).

[0105] In an embodiment, the high potential is -0.3 to +0.1 V. In an embodiment, the high potential is -0. 1 V.

[0106] In an embodiment, the low potential is -0.4 - 0 V. In an embodiment, the low potential is -0.2 V.

[0107] An embodiment is a binding protein immobilized electrode comprising a BHBBP as described herein, immobilized on an electrode. An embodiment is a biosensor for assaying BHB concentration comprising the binding protein immobilized electrode as a working electrode.

[0108] An embodiment is a continuous ketone monitoring system, comprising:

[0109] i) a BHBBP, a binding protein immobilized electrode, or biosensor as described herein; and ii) a) a light source and a light detection means, or

[0110] b) a means for applying voltage across a sample, and a means for detecting current.

[0111] DISCUSSION AND EXAMPLES

[0112] Handheld point-of-care tests (POCT) or personal use sensors for the measurement of BHB are constructed like blood glucose monitors (BGM): an oxidoreductase to catalyzes the oxidation of substrate, which in the case of ketone monitoring is BHB.

[0113] Now, R-3-hydroxybutyrate dehydrogenases (BHBDh, E.C. 1.1.1.30) are the only enzy mes discovered in nature which catalyze the oxidation of BHB. BHBDh is a NAD+ / NADH dependent oxidoreductase that catalyzes the conversion of BHB to acetoacetate (Figure 1A). BHB is a chiral molecule at the 3’ hydroxyl group which means there are two enantiomers, R / D and S / L. BHBDhs show strict stereo-specificity to the D-enantiomer, R-3-hydroxybutyrate as a substrate. As a result of this specificity', only R-3 -hydroxy butyrate is produced through normal metabolism by the reduction (reverse reaction of BHB oxidation) of acetoacetate. Thus, R-3-hydroxy butyrate is the normal product of human metabolism, which is the target molecule of ketone sensing. BHBDh is found in large variety of species from microorganisms to mammals. For diagnostic purposes, only bacterial-derived BHBDhs have been recombinantly produced and incorporated as elements of electrochemical biosensors [13-23], BHBDhs derived from Pseudomonas sp. (particularly Pseudomonas lemoignei) and Arthrobacter faecalis derived BHBDhs are commercially available for diagnostic use.

[0114] BHB sensing, using BHBDhs, is based on the quantification of NADH production by the reaction of BHBDh. Thus, NAD-dependent enzy me-based sensor platforms can be applied for BHB sensing. All commercially available hand-held BHB sensors, aswell as the state-of-the-art research utilize BHBDhs with hardware and test strip designs that are similar to blood glucose monitors.

[0115] In situ, real-time continuous measuring system of metabolite is only commercially available for glucose.

[0116] Continuous measurement of nutrients and metabolites in their natural environment through in situ, real-time monitoring systems offers several advantages. Placing the measurement system directly in the environment where the target analytes exist, such as in vivo physiological monitoring or in situ fermentation monitoring systems, allows for more effective feedback control with minimal or no time-lag. Additionally, this approach eliminates concerns regarding contamination in sampling operations.

[0024] , Although the development and adoption of these systems is expected to accelerate moving forward, most commercially available sensors are point-of-care, except for glucose monitoring. Highly effective continuous glucose monitoring (CGM) systems have been realized with a combination of excellent molecular recognition elements and innovative electrochemical / optical measurement principles

[0025] ,

[0117] Commercial enzyme-based continuous glucose monitors (CGMs) use electrochemical glucose sensors that are inserted under the skin to measure glucose concentration in interstitial fluid (ISF). These sensors employ glucose oxidase (GOx), an enzyme that catalyzes the oxidation of glucose, and electrochemically detect the resulting reaction either by monitoring hydrogen peroxide or by using a synthetic electron acceptor (mediator) to detect the reduced mediator on the electrode. GOx is able to catalyze this reaction due to its redox cofactor, flavin adenine dinucleotide (FAD), which is tightly bound to the enzyme, enabling a variety of sensor configurations. Advances in GOx technology, along with miniaturized electronics, surface coatings, and electrode materials, have accelerated the development of CGMs, including sensor-augmented insulin pump therapy, artificial pancreas systems, and the replacement of self-monit oring of blood glucose for type II diabetic patients.

[0025] ,

[0118] In comparison to GOx, BHBDh relies on NAD+ / NADH as a mandatory redox cofactor in the reaction solution. However, due to the complexity of NAD+ / NADH redox-chemistry and the necessity of having free NAD+ available in the reaction mixture, developing a continuous monitoring system using this enzy me has been a technological challenge. There have been only two reports about the construction of CKM systems using BHBDh [26. 27], A research group has reported the development of a microneedle-based continuous ketone monitoring (CKM) system

[0026] , Theyachieved this through the creation of a functional multilayer reagent which was coated on a microneedle biosensor. The biosensor employed an ionic liquid (IL) based carbon paste transducer electrode integrated with a phenanthroline-dione mediator, a mixed BHBDh / NAD+ layer, and glutaraldehyde cross-linking. Additionally, they coated the biosensor with chitosan and polyvinyl chloride as outer polymer layers. The use of IL, an imidazolium-based cation, and trifluoromethyl sulfonylimide anionic groups, played a significant role in confining and stabilizing NAD+ through hydrogen bonding, Coulombic interactions. Overall, this imparted fouling-resistant and highly sensitive anodic detection of NADH. Another group, also employing BHBDh as the enzyme, reporting the single clinical site in vivo study with the continuous ketone sensor

[0027] , According to their research article, they constructed a ketone sensor with BHBDh, similar to their glucose sensor. Although the article did not disclose the method for retaining NAD+ / NADH at the electrode surface, BHBDh, “... . and a proprietary' redox mediation chemistry containing osmium complex [were] deposited on the sensing layer to allow for selective oxidation of BHB and transport of electrons from the enzyme to the electrode using the wired enzyme technology”. Thus, this sensor was stable for 14 days of continuous ketone monitoring in ISF with the healthy subjects. The in vitro study revealed that the sensor response covers the BHB range up to 8mM, like a disposable ketone sensor which is already a commercial product.

[0119] Binding proteins; alternative biosensing molecules to enzyme for continuous monitoring

[0120] Target-specific binding proteins (TsBPs) such as periplasmic binding proteins (PBPs) and transcription factors, have been extensively researched and employed in biosensing systems [28. 29], Unlike enzymes, TsBPs do not catalyze the reaction of target molecules, but rather recognize and bind their targets specifically and reversibly. Upon binding, TsBPs undergo a conformational change that can be monitored spectroscopically (via fluorometry) or electrochemically

[0028] , PBPs, which are naturally associated with ATP-binding cassette (ABC) transporters and play a role in the cellular uptake of various molecules, have been extensively studied and utilized in the construction of biosensing systems

[0030] , PBPs are composed of two binding domains linked via a hinge region that dynamically changes its conformation upon ligand binding. This is depicted in Figure IB, which depicts schematically the structural change periplasmic binding proteins (PBPs) undergo when they bind orunbind with ligand. On the right side of Figure IB is a schematic depicting how PBPs have been used in biosensors.

[0121] Numerous biosensing principles have been reported, including optical biosensors using PBPs modified with fluorescence probes [31-33], and electrochemical sensors using PBPs modified with redox probes

[0034] , A fluorescence probe-modified glucose- galactose-binding protein was reported in a clinical trial of an in vivo CGM system

[0035] , like an enzyme-based CGM. Although electrochemical sensors employing redox- probe-modified PBPs have been demonstrated in a batch-wise sensing system, continuous monitoring systems have yet to be developed. Electrochemical sensors that use PBPs are based on monitoring the conformational change that occurs upon binding to the target, which causes the dynamics of the redox probe attached to the PBPs to change. This change can be detected using voltammetry methods, such as square wave voltammetry (SWV). Intermittent pulse amperometry (IP A) has been used to measure changes in electron transfer efficiency which is achieved by alternating between oxidation and reduction potentials. IP A is considered simpler and more suitable for continuous monitoring than SWV, as it does not require sweeping potential and enables charging-free sensing with low detection limits. The simple and versatile principle of IPA encouraged the development of a continuous electrochemical biosensing system for glutamine that employed a redox-probe-modified PBP

[0049] ,

[0122] This research is derived from developing and screening of new biosensing molecules for BHB detection, and has identified several binding proteins that specifically recognize BHB, which are referred to herein as BHB binding proteins (BHBBPs). BHB binding proteins have been found (BHBBPs) that are an ideal candidate for the development of an electrochemical BHBBP-based sensor for continuous BHB monitoring. These new BHBBPs were discovered as putative proteins in the genomic information from several bacteria, as non-annotated putative protein molecules, whose functions have not yet been elucidated nor predicted, including the ones derived from thermophilic bacteria, which can grow at optimum temperatures around 80 °C. resulting in super stable protein molecules. It was confirmed that the recombinantly produced BHBBP can bind to BHB and change its conformation based on BHB concentration, as determined by intrinsic fluorescence. By combining this achievement with previous development of an electrochemical sensor using PBP, an innovative CKM sensing system has been created.

[0123] The disclosed subject matter is further described in the following non-limiting Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only.

[0124] Example 1 - Preparation of BHBBPs

[0125] Amino acid sequences of BHBBPs, derived from Thermus thermophilus, Paucimonas lemoignei, and Ensifer meliloti (RefSeq identifiers: WP 244347939.1, WP 132259322.1, and WP_004435262.1) Figures 2A, 2B, and 2C show the amino acid sequences of putative ABC transporter R-|B-hydroxybutyrate binding proteins (BHBBPs) derived from Tt.2 [T. thermophilus], EDC24 [P. lemoignei], SMc [E. meliloti], respectively, and their chemically synthesized structural genes (Figures 2D, 2E, and 2F. respectively), which were chemically synthesized with restriction sites for recombinant production in E. coli. These hypothetical proteins are annotated as ABC transporter substrate-binding proteins, but the cognate ligands have not yet been elucidated and were unknown prior to these investigations. Putative BHBBP sequences from the following organisms are shown:

[0126] Tt.2 BHBBP: Thermus thermophilus (WP_244347939.1) (“Tt.2”)

[0127] MLRYRLTRRGVLRLGLGSAALAFTGRAOGETIRVGFVGPLSGVYAALGRN EVEGARM AVDDVNVQGGVLGRRLELLVEDSATRTDLGVQKLRKLVERDRIQ FSLGEVSSGVSLALSQAAAEYKMLHIVTGGHADDITGKSCRWNTFRIPTSGTM EARAIGPLLAERFGKNWYIITPDYAYGWSLQEAFTRVVERLGGKVLGADRVP LGTSDYSAVLLKAARAKPDVLLTFQAGDDAVAILKQIIQFGLDKQMAIAGGLQ EWENIAALPKEARIGWWTFEWYWIQPDVPEVKTFVDRYRRRYRKVPTARSW FGYAAVWSLALAIQKAKSLDSVKVAQALEGLELPRNVALQPGRVYYRKEDH QLLTGVFVGRVRQGQDPDDLFEVVRVVPGEEAAPDPRDTGCRIVYPG (SEQ ID NO: 1)

[0128] EDC24 BHBBP: Paucimonas lemoignei (WPJ32259322.1) (“EDC24”)

[0129] MKLKKLASFMCAALGSLAIONAQAADAISDGVVKVGVMTDMSGVYSAL AGQGSVVAAKMAIEDIGGKLLGKPVELVSIDHLNKPDIAASKAREWFDNDKV DMITDLVTSSVGLAVQQVARDKNRITINSGAGSTALTNKNCSPTGIHWAYDTY ALANGTGNAMVKDGNDSWYFVTADYAFGHSLETETANVVKANGGKVLGSV RHPLSASDFSSFLISAQSSGAKAIGLANAGADLTNAIKQAREFGINKKQKLASL LMFITDVHGLGLESAQGLYLTEGFYWDMDNETRAWSKRFFERHKKMPTMVH AGVYSSMMHYFKAIQAAGTDEAQAVMAKMRELPVKDFFARNGKLRADGRMVHDMYLMQVKAPNESKYPWDYYHIRRVIPADQAFMPLDKSECPLVKK (SEQ ID NO: 2)

[0130] SMc BHBBP: Ensifer meliloti (WP_004435262.1) (“SMc”)

[0131] MHKKLIATLAMVLAGSTAALADASDGKVKIGILNDOSGVYADFGGKSSYE AALMAVEDFGGKVLGVPVEVVTADHQNKPDIASNIARQWYDTEQVDSIMEL TTSSVALAVQAISKEKKKIDIVTGAATTELTGKQCSPYGFHWAYDTHSLAVGT GGALVKQGGDSWFFLTADYAFGYSLEENTGNYVKENGGTVVGAVRHPLATT DFSSFLLQAQSSGAKVIGLANAGLDTSNAIKQAAEFGIVQGGQRLAALLFTLA EVHGLGLDAAQGLTLTEGFYWNRDEESAKFGKRFMERTGKMPNMVHAGTY SAVLQYLKAIEKAGTDETEAVAKELHALPVDDVFAKNGTVAPNGRMIHDMY LLEVKKPDESKEPWDYFKVLATIPGKEAFIDPAQSGCELVKS (SEQ ID NO:3)

[0132] The underlined regions are predicted by SignalP 6.0 to comprise signal peptide.

[0133] The corresponding synthesized genes are as follows:

[0134] Tt.2:

[0135] CATATGAAGCTGAAGAAACTGGCCAGCTTTATGTGTGCAGCACTGGGT AGCCTGGCAATTCAGAATGCACAGGCAGCAGATGCAATTAGTGATGGTGT TGTTAAAGTTGGTGTGATGACCGATATGAGCGGTGTTTATAGCGCACTGGC AGGTCAGGGTAGCGTTGTTGCAGCAAAAATGGCAATTGAAGATATTGGTG GTAAACTGCTGGGTAAACCTGTTGAACTGGTTAGCATTGATCATCTGAACA AACCGGATATTGCAGCAAGCAAAGCACGTGAATGGTTCGATAATGATAAA GTGGATATGATCACCGATCTGGTTACCAGCAGCGTTGGTCTGGCCGTTCAG CAGGTTGCACGTGATAAAAATCGTATTACCATTAATAGCGGTGCAGGTAGC ACCGCACTGACCAATAAAAACTGTAGCCCGACCGGCATTCATTGGGCCTAT GATACCTATGCACTGGCAAATGGTACAGGTAATGCAATGGTTAAAGATGG CAATGATAGCTGGTATTTTGTGACCGCAGATTATGCATTTGGTCATAGCCT GGAAACCGAAACCGCAAATGTTGTGAAAGCAAATGGTGGCAAAGTTCTGG GTAGCGTGCGTCATCCGCTGAGCGCAAGCGATTTTAGCAGCTTTCTGATTA GCGCACAGAGCAGCGGTGCAAAAGCAATTGGCCTGGCGAATGCGGGTGCCGATCTGACCAATGCAATTAAACAGGCACGCGAATTTGGCATCAACAAAAA GCAAAAACTGGCGAGCCTGCTGATGTTTATTACCGATGTTCATGGTCTGGG TTTAGAAAGCGCACAGGGTCTGTATCTGACCGAAGGCTTTTATTGGGATAT GGATAATGAAACCCGTGCATGGTCAAAACGTTTCTTTGAACGTCATAAAAA GATGCCGACAATGGTTCATGCCGGTGTGTATAGCAGCATGATGCATTATTT CAAAGCAATTCAGGCAGCCGGTACAGATGAAGCACAGGCCGTTATGGCAAAAATGCGTGAACTGCCGGTGAAAGATTTCTTTGCACGTAATGGCAAACTGCGTGCAGATGGTCGTATGGTGCATGATATGTATCTGATGCAGGTTAAAGCACCGAACGAAAGTAAATATCCGTGGGATTATTATCATATCCGTCGTGTTATTCCGGCAGATCAGGCCTTTATGCCGCTGGATAAAAGCGAATGTCCGCTGGTTA AAAAGAAGCTT (SEQ ID N0:4)

[0136] EDC24:

[0137] CATATGAAGCTGAAGAAACTGGCCAGCTTTATGTGTGCAGCACTGGGTAGCCTGGCAATTCAGAATGCACAGGCAGCAGATGCAATTAGTGATGGTGTTGTTAAAGTTGGTGTGATGACCGATATGAGCGGTGTTTATAGCGCACTGGCAGGTCAGGGTAGCGTTGTTGCAGCAAAAATGGCAATTGAAGATATTGGTGGTAAACTGCTGGGTAAACCTGTTGAACTGGTTAGCATTGATCATCTGAACAAACCGGATATTGCAGCAAGCAAAGCACGTGAATGGTTCGATAATGATAAAGTGGATATGATCACCGATCTGGTTACCAGCAGCGTTGGTCTGGCCGTTCAGCAGGTTGCACGTGATAAAAATCGTATTACCATTAATAGCGGTGCAGGTAGCACCGCACTGACCAATAAAAACTGTAGCCCGACCGGCATTCATTGGGCCTATGATACCTATGCACTGGCAAATGGTACAGGTAATGCAATGGTTAAAGATGGCAATGATAGCTGGTATTTTGTGACCGCAGATTATGCATTTGGTCATAGCCTGGAAACCGAAACCGCAAATGTTGTGAAAGCAAATGGTGGCAAAGTTCTGGGTAGCGTGCGTCATCCGCTGAGCGCAAGCGATTTTAGCAGCTTTCTGATTAGCGCACAGAGCAGCGGTGCAAAAGCAATTGGCCTGGCGAATGCGGGTGCCGATCTGACCAATGCAATTAAACAGGCACGCGAATTTGGCATCAACAAAAAGCAAAAACTGGCGAGCCTGCTGATGTTTATTACCGATGTTCATGGTCTGGGTTTAGAAAGCGCACAGGGTCTGTATCTGACCGAAGGCTTTTATTGGGATATGGATAATGAAACCCGTGCATGGTCAAAACGTTTCTTTGAACGTCATAAAAAGATGCCGACAATGGTTCATGCCGGTGTGTATAGCAGCATGATGCATTATTTCAAAGCAATTCAGGCAGCCGGTACAGATGAAGCACAGGCCGTTATGGCAAAAATGCGTGAACTGCCGGTGAAAGATTTCTTTGCACGTAATGGCAAACTGCGTGCAGATGGTCGTATGGTGCATGATATGTATCTGATGCAGGTTAAAGCACCGAACGAAAGTAAATATCCGTGGGATTATTATCATATCCGTCGTGTTATTCCGGCAGATCAGGCCTTTATGCCGCTGGATAAAAGCGAATGTCCGCTGGTTA AAAAGAAGCTT (SEQ ID NO: 5)

[0138] SMc:

[0139] CCATGGACAAAAAGCTGATTGCAACCCTGGCAATGGTTCTGGCAGGTAGCACCGCAGCACTGGCAGATGCAAGTGATGGTAAAGTTAAAATTGGCATCCTGAATGATCAGAGCGGTGTTTATGCAGATTTTGGTGGTAAAAGCAGCTAT GAAGCAGCACTGATGGCAGTTGAAGATTTTGGAGGCAAAGTTCTGGGTGT TCCGGTTGAAGTTGTTACCGCAGATCATCAGAATAAACCGGATATTGCAAG TAATATTGC CC GTC AGTGGT ATGATAC CGAAC AGGTTGATAGC ATTATGGA ACTGACCACCAGTAGCGTTGCACTGGCCGTTCAGGCAATTAGCAAAGAGA AAAAGAAAATCGATATTGTGACAGGTGCAGCAACCACCGAACTGACCGGC AAACAGTGTAGCCCGTATGGTTTTCATTGGGCCTATGATACCCATAGCCTG GCAGTTGGTACAGGTGGTGCACTGGTTAAACAAGGTGGTGATAGCTGGTTT TTC CTGAC C GC AGATTATGC ATTTGGTT ATAGC CTGGA AGAA AAC AC C GGC AACTATGTGAAAGAAAATGGTGGCACCGTTGTTGGTGCAGTTCGTCATCCG CTGGCCACCACCGATTTTAGCAGCTTTCTGCTGCAAGCACAGAGCAGCGGT GCAAAAGTTATTGGTCTGGCAAATGCAGGTCTGGATACCAGCAATGCAATT AAACAGGCAGCAGAATTTGGTATTGTTCAAGGTGGTCAGCGTCTGGCAGC ACTGCTGTTTACCCTGGCCGAAGTTCATGGTCTGGGTTTAGATGCAGCACA GGGTCTGACACTGACCGAAGGTTTTTATTGGAATCGTGATGAAGAAAGCG CCAAATTCGGTAAACGTTTTATGGAACGTACCGGCAAAATGCCGAATATG GTTCATGCAGGCACCTATAGCGCAGTTCTGCAATATCTGAAAGCAATTGAA AAAGCAGGCACCGATGAAACCGAAGCAGTTGCAAAAGAACTGCATGCACT GCCGGTTGATGATGTTTTTGCCAAAAATGGTACAGTTGCACCGAATGGTCG TATGATCCATGATATGTATCTGCTGGAAGTTAAAAAGCCGGATGAAAGCA AAGAACCGTGGGATTATTTCAAAGTGCTGGCAACCATTCCGGGTAAAGAA GCATTTATTGATCCGGCACAGAGCGGTTGTGAACTGGTGAAAAGCAAGCTT (SEQ ID N0:6)

[0140] The underlined regions denote restriction sites: Ndel. Hindlll, and Xhol.

[0141] Figure 3 shows the vector plasmids, from left to right, pET28a-Tt.2, pET28a- EDC24 BHBBP, and pET22b-SMc BHBBP for the expression of each BHBBP, respectively. Specifically, Figure 3 shows expression vectors subcloned with putative structural genes of BHBBPs derived from these three organisms. The expression vectors for Tt.2 and EDC24 BHBBP are based on pET28a with sequences for encoding a signal peptide (MGSSHHHHHHSSGLVPRGSH (SEQ ID NO:7)) and a 6xHis tag (either LEHHHHHH (SEQ ID NO: 8) or KLAAALEHHHHHH (SEQ ID NO:9)) on the N and C termini, respectively. The expression vector for SMc BHBBP is based on pET22b with signal peptide removed, and sequences for encoding a pelBtag (MKYLLPTAAAGLLLLAAQPAMA (SEQ ID NO: 10) fused at the N-terminus, and 6xHis tag (KLAAALEHHHHHH (SEQ ID NO:9)) on the C-terminus.

[0142] Figure 4A shows the recombinant production and purification processes for BHBBPs. E. colt transformants harboring either pET28a-Tt.2 BHBBP, pET28a-EDC24 BHBBP, and pET22b-SMc BHBBP were used to expressed BHBBP with ZYP-5052 autoinduction media in both soluble (S), insoluble (I) fractions, and media (M) fractions. Tt.2 BHBBP expressed markedly better than the other two BHBBPs. which were identified by SDSPAGE analyses, revealing the recombinant BHBBP was produced in the expected molecular weight (with signal sequence; 46.2 kDa, without signal sequence; 42.3kDa) in the soluble fraction.

[0143] Figure 4B shows the chromatograms from the purification of each protein using nickel affinity or nickel affinity + size exclusion chromatography, depending on the quantity and purity of the recovered sample. The column used for His tag affinity chromatography was a HisTrap HP (5 mL). The A buffer comprised 20 mM Imidazole, 500 mM NaCl, lx PBS, pH 7.4, while the B buffer comprised 500 mM Imidazole, 500 mM NaCl, lx PBS. pH 7.4. The gradient used was B 0-80% / 15 CV at a flow' rate of 5 mL / min. A clear beak was observed in fractions C2-D9, which were applied for SDSPAGE.

[0144] Example 2 - Characterization of the purification products by electrophoresis

[0145] Figure 5 shows SDS-PAGE analysis of purified recombinant putative BHBBPs derived from Thermus thermophilus in E. coli after affinity' chromatography. A clear induced band corresponding to Tt.2 without its signal peptide (382 amino acids, 42.3 kDa, as opposed to with its signal peptide, expected to have 416 amino acids, and be 44.2 kDa) was observed in the soluble fraction, as almost a single band, denoted with an arrow. The production yield of Tt.2 calculated after purification was a ~20 mg / L culture. The three rightmost lanes are as follows:

[0146] SC: Supernatant after centrifuge

[0147] FT: Flowthrough

[0148] Wa: Column wash prior to elution

[0149] Fractions C4-D11 were gathered and treated as purified protein, to be used for autofluorescence / electrochemical measurement.

[0150] These results indicated the recombinantly produced putative protein, derived from Thermus thermophilus, WP 244347939. 1 was successively purified with expected molecular weight without its inherent signal peptide for the secretion. These resultsindicated success in producing the proteins with enough yield to effectively characterize their activity.

[0151] Example 3 - The binding of putative protein toward BHB.

[0152] Auto-fluorescence analyses of recombinantly produced and purified putative BHBBP derived from Thermus thermophilus in E.coli were performed as a representative example for the other ketone binding candidates.

[0153] A FP-8050 fluorometer from JASCO was used. The excitation wavelength was 295 nm, and emissions were observed at 315-360 nm, with a sampling pitch of 0.2 nm, 10 nm bandwidth, and a peak at 329 nm. The (intrinsic) autofluorescence observed at around 329 mn as a result of excitation at 295nm is derived from tryptophan and tyrosine residues in the protein structure. Figure 6A shows how BHBBP with native tryptophan / tyrosine residues is affected by the binding of BHB, or a control compound, creating binding-induced conformational change which alters the intrinsic fluorescence of the residues. The binding protein concentration was 0.4 pM. and the BHB concentration ranged from 7.49 nM to 2222.22 nM.

[0154] As shown in Figure 6B, depicting averaged emission spectra for varying BHB concentrations, the fluorescence peak at around 329 nm decreases with increasing BHB concentration with respect to a reference cuvette. This observation demonstrates that this putative BHBBP can recognize and change its conformation in the presence of BHB, in BHB concentration dependent manner. These results revealed that this molecule is BHB.

[0155] Example 4 - Fluorescence based BHB monitoring using BHBBP

[0156] Figures 7A-7B show the auto-fluorescence dependency on BHB concentration, for Tt.2 (Fig. 7A) and EDC24 BHBBP (Fig. 7B), with chiral BHB quantification from —15-2222 nM, with a reference cuvette. Frozen protein aliquots were thawed from -80 °C., and brought to concentrations of about 0.4 pM (with a normalized final intensity between 3000-6000 units. Stocks of titrant were prepared from lOx ligand solution and 0.5 pm protein (to prevent signal decay). These were then titrated according to the volume / concentration scheme. Spectrofluorometer measurements were taken in the same manner as in Example 3, with the same instrumentation parameters and concentrations, with 3 technical replicates for each measurement. Error bars represent the standard deviation.

[0157] The (intrinsic) autofluorescence observed at around 329 nm increased with increase of BHB concentration in the solution. By plotting relative change valuesversus BHB concentration, the fluorescence intensity change can be used as the BHB concentration index. In other words, these results clearly demonstrated that by monitoring fluorescence change of BHBBP, BHB concentration can be determined. Therefore, these results and facts guarantee that BHBBP can be used as a biosensing molecule for a fluorescence-based BHB sensing system.

[0158] Example 5 ~ Purification and characterization ofTt.2 and EDC24 BELBBPs

[0159] Figure 8 depicts the purification of Tt.2 and EDC24 BHBBPs. A plasmid was prepared according to Figure 8. 3 mL of LB and 50 pg / mL of Km was inoculated with BL21 LOBSTR glycerol stock, and was stirred at 37 °C overnight, at 250 rpm. A 1% inoculation of overnight test culture was prepared, and 100 mL ZYP-5052 media (20x NPS (50 mM KH2PO4, 50 mM Na2HPO425 mM (NH4)2SO4), 50x 5052 (0.5% glycerol, 0.05% glucose, 0.2% a-lactose), 1 mM MgSO4, and LB media) plus 50 pg / mL of Km was added. The mixture was stirred at 30 °C for 24 hours, at 180 rpm. The cells were harvested, and centrifuged at 8000 xg, at 4 °C for 10 minutes. The pellet, containing wet cells, was then treated via disruption or osmotic shock.

[0160] For cell disruption, the pellet was resuspended in A buffer, and subjected to French press at 2000 psi. The resulting mixture was centrifuged at 13,000 x g at 4 °C for 30 minutes, then the supernatant was ultracentrifuged at 30,000 x g at 4 °C for 60 minutes. The supernatant was diluted and filtered through a 0.22 micron Millipore filter in preparation for affinity chromatography.

[0161] The results of the nickel affinity purification are shown, for Tt.2 BHBBP (top chart) and EDC24 (bottom chart). Identified fractions were analyzed by SDS page, and then western blot (Tt.2 on top, and EDC24 on bottom). The Western blots demonstrated a single population for each BHBBP.

[0162] The Tt.2 BHBBP’s intrinsic fluorescence was then tested. Without being bound by theory, it is believed that when BHB or a control compound is introduced to a binding protein, binding-induced conformational change alters the intrinsic fluorescence of residues.

[0163] Protein aliquots were thawed from -80 °C. Next, the concentration of protein was brought to about 0.4 pM (with final intensity normalized between 3000-6000 units). Finally, stocks of titrant were made from lOx ligand solution and 0.5 pM protein, to prevent signal decay. The stocks were titrated directly according to the volume / concentration scheme. Fluorescence intensity at different wavelengths and BHB concentration (nM) is shown in Figure 9A (n=3, independent experimentalcurves). Figure 9B (also n=3, independent experimental curves) shows relative peak fluorescence change (%) for varying concentrations of BHB. Relative intensity changes were calculated with respect to a reference cuvette, which was titrated with the same volume of solution. Measurements were taken on a Jasco Spectrofluorometer (295 nm excitation, 315-365 nm emission sweep). Error bars represent standard error of the mean between 3 experiments.

[0164] In further experiments, protein aliquots were again thawed from -80 °C. Next, the concentration of protein was brought to about 5 pM (with final intensity normalized between 1500-3000 units). Finally, stocks of lOx compound were prepared by serial dilution from 100 mM stock. Thes stocks were pre- incubated in tubes for 30 minutes, according to the volume / concentration scheme. One tube consisted of 5x protein (about 1 pM final concentration, depending on the final intensity normalization), lx PBS, and lOx compound (BHB or control), incubated together at room temperature. Figure 9C (n=4 samples within the same experiment) shows fluorescence intensity for 10 pM solutions of L-ala, AcAc, and BHB, and a blank. Figure 9D (also n=4 samples within the same experiment) shows another way of depicting the fluorescence intensity from the samples analyzed in Figure 9C.

[0165] Figures 10A-10D show results from experiments identical to those described in Figures 9A-9D, but using EDC24 instead of Tt.2.

[0166] Figure 11 shows the results of isothermal calorimetry tests using Tt.2 and R-BHB, and compares the results to previously reported KD values for putrescine binding protein (BP), arginine BP, and maltose BP. The KD value is determined by the following equation:

[0167] AG =AH- TAS = RTInKD

[0168] The interaction of Tt.2 and (R)-[3-HB is endothermic, which means the spontaneity of binding is driven primarily by entropic changes. The results align preliminary results align well with the autofluorescence data (KD within the error for both sets of experiments).

[0169] Figure 12 demonstrates isothermal calorimetry using Tt.2 and controls.Experimental parameters are described in Figure 12, along with charts showing the kcal / mol of inj ectants, including BHB, acetoacetate, and L-alanine, compared to their molar ratio. On the right side of Figure 12 is a representative control titration curve. The time course plot (top) is the raw data obtained from the control titration, while the molar ratio plot (bottom) shows the fitting for titration of L-alanine. As shown in thetable in Figure 12, the interactions of acetoacetate and L-alanine are not endothermic and show 2000-4000 times the apparent KD.

[0170] Finally, Figure 13 shows differential scanning fluorimetry (nanoDSF) data for Tt.2 and EDC24. Differential scanning fluorimetry (nanoDSF) is a biophysical technique that combines fluorescence spectroscopy and differential scanning fluorimetry to analyze protein stability and thermal unfolding. It measures changes in protein fluorescence as a function of temperature, providing insights into protein folding, stability, and interactions in a high-throughput manner; the denaturation, and the associated change in Trp fluorescence, is shown on the left side of Figure 13. The right side shows the tryptophan fluorescence (top) and the first derivative thereof (bottom), for EDC24 (blue) and Tt.2 (gray).

[0171] Example 6 - IPA based continuous ketone monitoring with arPES modified Tt.2 BHBBP immobilized gold disk electrode

[0172] Figure 14 shows the process of immobilizing gold disk electrodes with BHBBP and its subsequent by redox probe, amine reactive PES (arPES). A 2 mm gold disk (CH 101, CH Instruments) was cleaned, and then soaked in a SAM solution (50 pM NTA-SAM in EtOH; 200 pl in a 500 pl tube), overnight at room temperature (approximately 21 °C). The disk was then rinsed with EtOH. Next, the disk was soaked in 40 mM NiCh solution (200 pl in a 500 pl tube), for one hour at room temperature. The disk was then rinsed with 20 mM HEPES pH 7.8. After that, the disk was soaked in 17 uM Tt.2 BHBBP in PBS (100 pl in a 500 pl tube) overnight at 4 °C, followed by rinsing with PB. Finally, the disk was soaked in 1.7 mM arPES (100 pl in a 500 pl tube) for about 30 minutes at room temperature, and then rinsed in PBS, to provide a Au / NTA-SAM / PES-TtBHBBP2 surface.

[0173] This figure also shows the electrochemical method to monitor BHB using BHBBP immobilized electrode, intermittent pulse amperometry.

[0174] An electrochemical sensing method of BHB using BHBBP-immobilized electrodes in a buffer was also tested. A 3-electrode configuration was used:

[0175] WE: PES-TtBHBBP2 immobilized Au disk electrode

[0176] CE: Pt wire

[0177] RE: Ag / AgCl (CHI1111, CH Instruments)

[0178] The cell volume was 10 mL. The solution used was either 100 mM PPB pH 7.4 buffer or artificial ISF (“alSF,” comprising 123 mM NaCl, 3.5 mM KC1, 2.5 mMCaCh, 0.7 mM MgCh, 1.5 mM NaH2PO4, and 10 mM HEPES), under 250 rpm stirring, with varying concentrations of BHB or glucose (as a control) added.

[0179] IPA measurement was carried out by applying an alternating potential of - 0. 1 V vs. Ag / AgCl (oxidation potential of PES) and -0.2 V vs. Ag / AgCl (reduction potential of PES) for 10 cycles every 5 min and monitoring the resultant current. Each potential was applied for 20 seconds. Figures 15-18 show the current response from intermittent pulse amperometry (IPA) measurement of BHB in buffer solution.

[0180] Figure 15 shows the entire raw data of the voltammogram from IPA measurement in buffer (100 mM PPB at pH 7.4). Specifically, the top portion of Figure 9 shows the raw data obtained with the IPA measurement, while the bottom shows the enlarged graph of the current signal from one of 10 cycles of alternating potential application. Each potential (-0. 1 or -0.2 V) was applied for 20 ms. Alternating potential was applied for 10 cycles every 5 minutes. The average of the peak currents from the last three cycles was used to prepare the calibration curves.

[0181] Figure 16 and Figure 17 demonstrate peak oxidation and reduction current change, respectively, in the presence of different BHB concentrations using glucose as a negative control. Specifically, Figure 16 depicts BHB dependent oxidation current change from IPA measurement in buffer solution (100 mM PPB pH7.4). The peak current change in IPA measurement dependent on exponentially-increasing BHB concentrations was investigated based on the structural change by the binding of BHB to TtBHBBP2. The top of Figure 16 shows the graph of the raw data only for the oxidation current region. The bottom of Figure 16 shows a plot of oxidation peak cun-ent change against time from different concentration of BHB, with glucose as a control.

[0182] Similarly, Figure 17 depicts BHB dependent reduction current change from IPA measurement in buffer solution (100 mM PPB pH7.4). The peak current change in IPA measurement dependent on BHB concentration was investigated based on the structural change by the binding of BHB to TtBHBBP2. The top of Figure 17 shows the enlarged graph of the raw data only for the reduction current region. The bottom of Figure 17 shows the plot of reduction peak current change against time from different exponentially- increasing concentrations of BHB and glucose as the control.

[0183] An increase in peak current from the addition of BHB was observed for both oxidation and reduction current. These results suggest the initial feasibility of electrochemical BHB monitoring with IPA using redox probe-modified BHBBPs.

[0184] Figures 18A-18F shows IPA-derived calibration curves with respect to increasing BHB concentration using 3 independently prepared PES-BHBBP immobilized electrodes in buffer solution (100 mM PPB at pH 7.4). The figures show peak current change dependency on BHB concentration without significant change from glucose for both oxidation and reduction current. Standard deviation for the 3 electrodes is shown as the error bar in each point.

[0185] Specifically, Figures 18A and 18B depict oxidation calibration curves with a normal and logarithmic x axis, respectively. Figure 18C depicts the change in oxidation current. The ACurrent was calculated by subtracting the peak current value in the absence of BHB from the peak current value in the presence of various concentrations of BHB.

[0186] Similarly, Figures 18D and 18E depict oxidation calibration curves with a normal and logarithmic x axis, respectively. Figure 18F depicts the change in oxidation current. The ACurrent was calculated in the same manner as above.

[0187] Figures 18A-18F, together, demonstrate that BHB concentration can be determined in buffer solution with IPA using BHBBP immobilized electrode, with the BHB concentration between 0.1 pM to 100 pM.

[0188] Example 7 - The electrochemical sensing method of BHB using BHBBP immobilized electrode in artificial ISF.

[0189] Figures 19 and 20 show the monitored current response of intermittent pulse amperometry (TP A) measurement of BHB binding to TtBHBBP2 in artificial interstitial fluid (alSF) solution, for oxidation and reduction, respectively. IPA measurement was carried out by applying alternating potential of - 0. 1 V vs. Ag / AgCl (oxidation potential of PES) and -0.2 V vs. Ag / AgCl (reduction potential of PES) for 10 cycles every 5 minutes, and monitoring the resulting current. Figure 19 and Figure 20 show the peak current change in the presence of various exponentially-increasing concentrations of BHB and glucose as the negative control for oxidation current and reduction current, respectively.

[0190] Specifically, the top of Figure 19 shows an enlarged graph of the raw data for the oxidation current region. The bottom of Figure 19 shows a plot of oxidation peak current change against time from different exponentially-increasing concentrations of BHB, with glucose as a control.

[0191] Figure 20 shows the peak current change in the presence of various concentration of BHB and glucose as the negative control for reduction current. Specifically, the topof Figure 20 shows an enlarged graph of the raw data for the reduction current region, respectively. The bottom of Figure 20 shows a plot of reduction peak current change against time from different concentrations of BHB, with glucose as a control.

[0192] The increasing of peak current by the addition of BHB was observed for both oxidation and reduction current. These results suggest that BHB concentration can be monitored electrochemically in an artificial ISF solution, using an electrode immobilized with redox probe-modified BHBBP and intermittent pulse amperometry.

[0193] Example 8 - The electrochemical sensing method of BHB using BHBBP immobilized electrode in artificial ISF (alSF).

[0194] Figures 21A-21F shows the calibration curves from intermittent pulse amperometry (IPA) of BHB using 3 independently prepared PES-BHBBP immobilized electrodes in alSF solution. Each figure shows peak current change dependency on BHB concentration without significant change on glucose for both oxidation and reduction current in alSF. Standard deviation for the 3 electrodes is shown as the error bar in each point.

[0195] Specifically, Figures 21A and 2 IB depict oxidation calibration curves with a normal and logarithmic x axis, respectively. Figure 21C depicts the change in oxidation current. The ACurrent was calculated by subtracting the peak current value in the absence of BHB from the peak current value in the presence of various concentrations of BHB.

[0196] Similarly, Figures 21D and 21E depict reduction calibration curves with a normal and logarithmic x axis, respectively. Figure 21F depicts the change in reduction cun-ent. The ACurrent was calculated in the same manner as above.

[0197] Figures 21A-21F show that that BHB concentration can be determined in alSF solution with IPA using BHBBP immobilized electrode, with a BHB concentration between 1 pM to 1000 p M . An increase in current was observed for both oxidation and reduction cun-ent from 1 to 1000 pM BHB; thus, using buffer instead of alSF showed an increase in current when measured at lower concentration (from 0. 1 pM), as shown in Figures 18C and 18F.

[0198] Example 9 - Electrode preparation and use

[0199] Figure 22 shows a method scheme for preparing a PES-Tt2BHBBP immobilized gold wire electrode. The resulting apparent surface areas for three different wires (El, E2, and E3) are shown on the right side of Figure 22.

[0200] Figure 23 illustrates cyclic voltammograms of gold wire (left) and disk (rod) (right) electrodes with PES-modified BHBBP.

[0201] Figure 24 shows intermitted pulse amperometry (IPA) measurement using gold wire electrodes with PES modified BHBBP. A 3 -electrode configuration was used:

[0202] WE: Au wire / NTA-SAM / PES-BHBBP

[0203] CE: Pt wire

[0204] RE: Ag / AgCl

[0205] This was performed in 100 mM PPB at pH 7.4 and stirred at 250 rpm.

[0206] An alternating potential of +0. 1 V vs. Ag / AgCl (oxidation potential) and -0.2 V vs. Ag / AgCl (reduction potential) was applied. Each potential was applied for 20 ms, and alternating potential was applied for 10 cycles every 5min. The resulting current was monitored.

[0207] Figures 25 and 26 show the monitored current response of intermittent pulse amperometry (IPA) measurement of the gold wire electrode (El) in 100 mM PPB at pH 7.4, for oxidation and reduction, respectively. Figures 25 and Figure 26 show the peak current change in the presence of various exponentially increasing concentrations of BHB and glucose as the negative control for oxidation current and reduction current, respectively.

[0208] Specifically, the top of Figure 25 shows an enlarged graph of the raw data for the oxidation current region. The bottom of Figure 25 shows a plot of oxidation peak current change against time from different exponentially increasing concentrations of BHB, with glucose as a control.

[0209] Figure 26 shows the peak current change in the presence of various concentrations of BHB as the negative control for reduction current. Specifically, the top of Figure 26 shows an enlarged graph of the raw data for the reduction current region, respectively. The bottom of Figure 26 shows a plot of reduction peak current change against time from different concentrations of BHB.

[0210] Figure 27 shows calibration curves made from the data in Figures 25-26. Specifically, Figure 27, on the left side, depicts oxidation calibration curves with a normal (top) and logarithmic (bottom) x axis. Similarly, Figure 27, on the right side, depicts reduction calibration curves with a normal (top) and logarithmic (bottom) x axis.

[0211] Example 10 - updated results and further identification of sequences

[0212] Amino acid sequences of BHBBPs, derived from Paucimonas lemoignei, Noviherbaspirillum sedimenti, and Burkholderia mallei (RefSeq identifiers WP 243656789.1, WP_207907186.1, WP_119785162.1, WP_119785162.1).

[0213] Figures 28A, 28B, 28C, and 28D show the amino acid sequences of putative BHBBPs derived from Paucimonas lemoignei [EDC37, EDC10], Noviherbaspirillum sedimenti [NovoS], and Burkholderia mallei [BMA2936], respectively. These hypothetical proteins are annotated as ABC transporter substrate-binding proteins, but the cognate ligands have not yet been elucidated and were unknown prior to these investigations. Putative amino acid sequences are as follows.

[0214] The underlined regions are predicted by SignalP 6.0 (Danmarks Tekniske Universitet bioinformatic services) to comprise signal peptide.

[0215] EDC37 BHBBP: Paucimonas lemoignei (WP 243656789.1) (“EDC37”)

[0216] MKMNKKLTLLAAAVAGAFGISASASAADNVIKIGFITDMSGVYADFDGOG GVEAIKLAIADFGGAINGKKIELITADHLNKADVAADRAREWFDKQGVDLLIG GSNSAANLAMAKIAAEKKKVFISAGSGTTRLTNEECNPYTIQYAYDTTALARG TGAALTKQGGKSWYFLTVDYAFGTSLEKDTADVVKANGGKVMGSVKHPLS APDFSSFLLQAQASKAQVLGLANAGGDVINSIKAANEFGLTKSMKLAGMMIFI NDIHALGLSVTQGMYLTDGWYWDLNEDSRKWSARYFDKMKKMPSMFQAA DASATIQYLNAVKATGTTDADTIMAHLRKTKINDFFTKDGVVRPDGRMVHD MYLMQVKSPAESTRPWDYYKLVQTIPGEQAYMTKAESKCALWK (SEQ IDNO:11)

[0217] EDC10 BHBBP: Paucimonas lemoignei (WP_207907186.1) (“EDC10”)

[0218] MAMNFKRKFLTALVMSTLLGAGAAHASKDNVIRIGVLTDFSGTYADIAGK GALTAVEMAVEDFSKDRTVNGKKIEVIYADHLNKADIAASKAREWYDTQGV DIIVDLATSSAALAVTAIAEQKNKIALVTTGGALPLTNDKCTPVTLHWVYDTY SLTAGTAKTVVDSGKKSWYFITADYVLGHSLEQEAAKVVKANDGEVKGAAR HPFPGSDFSSYLMTAQSSKADVIALANAGSDLANTIKQANEFGITTSKQTVLPL LMFISDVHAMGLKTTQGLTLTEAFYWNRDEKTRAWARRFYQRAGKMPTSAQ AGDYSGVTNYLKAVKATGTTDTATVMKYLKSTPIDDGLFKGQIRADGRLAH DMLLVQVKSPAESKEPWDYYKIKSVIPADVATMPLSQSQCKLVKK (SEQ ID NO: 12)

[0219] NovoS BHBBP: Noviherbaspirillum sedimenti (WP_119785162.1) (“NovoS”)

[0220] MTMRMNRKIVSLAVAVAGTFGLAASACAADNVIKIGFITDMSGVYADFDGPGGVEAIKLAIADFGGVVNGKKIELIAADHLNKADVAAAKAREWFDSQGVDMLIGGANSAANLAMARIAAEKKKVFISAGSGTTRLTNEECNAYTIQYAYDTTA LARGTGAALTRQGGKSWYFLTVDYAFGTSLEKDTADIVKANGGKVVGSVKH PLSAPDFSSFLLQAQASKAQVLGLANAGGDTINAIKAANEFGVTKSMKLAGM LIFINDVHALGLDVTKGMYLTDGWYWDLNDDSRKWSARYFEKMKKMPSMF QAADASATIQYLNAVKATGTTDADTIMAHLRKTKINDFFTKNGVVRPDGRMV HDMYLMEVKSPAESKRPWDYYKLVQTIPGEQAYMTKAESKCALWK (SEQ IDNO:13)

[0221] BMA2936 BHBBP: Burkholderia mallei (WP_119785162.1) (“BMA2936”)

[0222] MKLKTLAHACLAVAAAWSVGAAQAADSVKIGFITDMSGLYADIDGQGGL EAIKMAVADFGGKVNGKPIEWYADHQNKADIAASKAREWMDRGGLDLLV GGTNSATALSMNQVAAEKKKVYINIGAGADTLTNEQCTPYTVHYAYDTMAL AKGTGSAVVKQGGKTWFFLTADYAFGKALEKNTADVVKANGGKVLGEVRH PLSASDFSSFLLQAQSSKAQILGLANAGGDTVNAIKAAKEFGITKTMKLAALLMFINDVHALGLETTQGLVLTDSWYWNRDQASRQWAQRYFAKMKKMPSSLQ AADYSSVTTYLKAVQAAGSTDSDKVMAQLKKMKIDDFYAKGYIRTDGSMIH DMYLMEVKKPSESKEPWDYYKVVATIPGEQAFTTKQETRCALWK (SEQ ID NO: 14)

[0223] Figures 29A, 29B, 29C, and 29D represent the chemically synthesized genes for recombinant production of EDC37, EDC10, NovoS, and BMA2936, respectively. The underlined regions are the restriction sites for subcloning.

[0224] EDC37:

[0225] CATATGAAGATGAACAAAAAGCTGACCCTGCTGGCAGCAGCAGTTGCC GGTGCATTTGGTATTAGCGCAAGCGCCAGCGCAGCAGATAATGTTATCAA AATTGGCTTCATCACCGATATGAGCGGTGTTTATGCAGATTTTGATGGTCA AGGTGGTGTGGAAGCAATTAAACTGGCAATTGCGGATTTTGGTGGTGCGATTAATGGCAAAAAGATTGAACTGATTACCGCAGACCATCTGAATAAAGCAG ATGTTGCAGCAGATCGTGCACGTGAATGGTTTGATAAACAGGGTGTTGATC TGCTGATTGGTGGTAGCAATAGCGCAGCAAATCTGGCAATGGCCAAAATT GCAGCCGAGAAAAAGAAAGTGTTTATTAGTGCAGGTAGCGGTACAACCCGTCTGACCAATGAAGAATGTAATCCGTATACCATCCAGTATGCCTATGATAC CACCGCACTGGCACGTGGTACAGGTGCAGCACTGACCAAACAAGGTGGTA AAAGCTGGTATTTTCTGACCGTTGATTATGCATTTGGCACCAGCCTGGAAA AAGATACCGCAGATGTGGTTAAAGCAAATGGTGGTAAAGTTATGGGTAGC GTTAAACATCCGCTGAGCGCACCGGATTTTAGCAGCTTTCTGTTACAGGCACAGGCAAGCAAAGCACAGGTTCTGGGTTTAGCAAATGCCGGTGGTGATGTGATTAATAGCATTAAAGCAGCCAATGAATTTGGCCTGACCAAAAGCATGAAACTGGCAGGTATGATGATCTTCATTAACGATATTCATGCACTGGGTCTGAGCGTTACCCAGGGTATGTATCTGACCGATGGTTGGTATTGGGATCTGAATGAAGATAGCCGTAAATGGTCAGCCCGTTATTTCGACAAAATGAAAAAGATGCCGAGCATGTTTCAGGCAGCAGATGCAAGCGCAACCATTCAGTATCTGAACGCAGTTAAAGCCACCGGCACCACCGATGCAGATACCATTATGGCCCATCTGCGTAAAACCAAAATCAACGATTTCTTCACCAAAGATGGTGTTGTTCGTCCGGATGGTCGTATGGTTCATGATATGTACCTGATGCAGGTTAAAAGTCCGGCAGAAAGCACCCGTCCGTGGGATTATTACAAACTGGTTCAGACCATTCCGGGTGAACAGGCATATATGACCAAAGCAGAAAGTAAATGTGCCCTGTGGAAAAAGCTT (SEO ID NO: 15)

[0226] EDC 10:

[0227] CATATGGCTATGAATTTTAAAAGGAAGTTCCTAACCGCGCTGGTGATGAGCACCCTGCTGGGTGCGGGTGCGGCGCACGCCTCGAAGGACAATGTTATCCGTATTGGTGTTCTTACTGACTTCTCTGGTACGTACGCAGACATTGCTGGCAAGGGCGCGCTGACTGCGGTAGAGATGGCAGTGGAGGATTTCTCCAAGGATCGTACCGTGAACGGTAAGAAGATCGAAGTGATCTATGCCGACCACCTGAATAAGGCGGACATCGCGGCTTCCAAGGCTCGCGAATGGTACGACACCCAAGGTGTTGATATTATCGTGGACCTGGCTACCAGCTCTGCAGCGTTGGCGGTAACCGCGATTGCCGAGCAGAAAAACAAAATCGCTTTGGTCACCACCGGTGGTGCTTTACCGCTGACGAACGATAAATGCACCCCAGTGACCCTGCATTGGGTTTATGACACCTACAGCCTGACTGCGGGCACCGCCAAAACCGTCGTCGACAGCGGCAAAAAGAGCTGGTATTTCATCACCGCCGACTACGTTCTGGGCCATAGCTTGGAACAGGAGGCGGCGAAAGTTGTTAAGGCGAACGATGGTGAAGTTAAGGGCGCTGCGCGCCACCCGTTCCCGGGTAGTGACTTCAGCAGCTATTTGATGACTGCGCAATCTAGCAAGGCGGACGTGATTGCGCTCGCTAACGCTGGCTCTGATCTGGCTAACACCATTAAACAAGCCAACGAATTTGGTATTACCACATCGAAGCAGACCGTGCTGCCGTTACTGATGTTTATTAGCGATGTTCATGCAATGGGTCTGAAGACCACGCAGGGTCTGACTCTGACCGAGGCATTTTACTGGAATAGAGATGAAAAAACGCGTGCCTGGGCACGCCGTTTTTACCAGCGTGCGGGCAAAATGCCGACCTCAGCGCAAGCAGGTGATTACAGCGGCGTTACGAATTATCTGAAAGCGGTCAAGGCCACCGGCACGACCGATACCGCTACGGTGATGAAATATCTCAAGTCCACCCCGATTGATGATGGCTTGTTTAAAGGTCAAATCCGCGCCGACGGCCGTTTGGCGCACGATATGCTGTTGGTTCAGGTGAAGTCCCCGGCAGAGTCCAAAGAGCCGTGGGATTACTATAAAATCAAAAGCGTGATCCCGGCAGACGTTGCAACGATGCCACTGAGCCAATCCCAGTGTAAACTGGTCAAAAAAAAGCTT (SEQ ID NO: 16)

[0228] NovoS:

[0229] CATATGACAATGAGAATGAATAGGAAAATAGTATCGCTGGCGGTGGCGGTTGCTGGTACGTTCGGCCTCGCGGCCAGCGCGTGTGCGGCCGACAATGTTATCAAGATTGGTTTTATCACCGACATGAGCGGTGTCTATGCTGATTTCGATGGTCCGGGTGGCGTGGAAGCAATCAAGCTCGCGATTGCCGACTTCGGTGGCGTCGTGAATGGTAAAAAGATCGAGCTGATCGCAGCGGACCACTTGAACAAAGCGGACGTAGCCGCAGCGAAAGCCAGAGAATGGTTTGACAGCCAGGGTGTTGATATGCTGATCGGCGGCGCGAATAGCGCAGCGAACCTGGCTATGGCACGTATTGCAGCTGAAAAGAAGAAAGTTTTTATTAGCGCGGGCAGCGGTACAACCCGCCTGACCAATGAGGAATGCAATGCATACACCATCCAATATGCGTATGATACTACGGCTCTGGCGCGCGGTACCGGCGCTGCGTTGACGCGTCAAGGCGGGAAAAGTTGGTACTTCCTGACTGTAGACTACGCTTTTGGCACCTCCTTGGAAAAAGATACGGCCGACATCGTGAAGGCCAACGGCGGTAAGGTGGTTGGTTCTGTTAAGCACCCGCTGAGCGCTCCGGATTTCTCTAGCTTTTTGCTGCAGGCGCAGGCGTCCAAGGCTCAAGTTCTGGGTTTGGCCAACGCGGGTGGCGATACGATCAACGCTATTAAAGCGGCGAACGAGTTCGGTGTGACCAAGTCCATGAAATTGGCTGGCATGCTGATTTTTATTAACGACGTGCACGCGCTGGGCTTAGATGTGACCAAAGGTATGTATCTGACGGACGGTTGGTACTGGGATCTGAACGATGACTCACGTAAATGGAGCGCGCGTTATTTCGAGAAGATGAAAAAAATGCCGAGCATGTTTCAGGCAGCGGACGCATCTGCTACCATCCAGTATTTGAATGCGGTCAAGGCGACCGGCACCACTGACGCCGATACCATTATGGCACATTTACGTAAAACCAAGATCAACGACTTCTTCACCAAGAACGGTGTGGTGCGTCCGGATGGCCGTATGGTTCATGATATGTACCTGATGGAGGTTAAGTCGCCGGCAGAGTCCAAGCGCCCATGGGATTACTACAAACTGGTTCAAACCATTCCGGGTGAACAGGCCTACATGACCAAGGCGGAGAGCAAGTGCGCACTGTGGAAAAAGCTT (SEQ ID NO: 17)

[0230] BMA2936:

[0231] CATATGAAGCTGAAAACCCTGGCACATGCCTGTCTGGCAGTTGCAGCAGCATGGTCAGTTGGTGCAGCACAGGCAGCAGATAGCGTTAAAATTGGTTTTATTACCGATATGAGCGGTCTGTATGCAGATATTGATGGTCAAGGTGGTCTGGAAGCCATTAAAATGGCCGTTGCAGATTTTGGTGGTAAAGTTAATGGTAAA CCGATCGAAGTTGTGTATGCCGATCATCAGAATAAAGCCGATATTGCAGCA AGCAAAGCACGTGAATGGATGGATCGTGGTGGCCTGGATCTGCTGGTTGG TGGCACCAATAGCGCAACCGCACTGAGCATGAATCAGGTTGCAGCCGAGA AAAAGAAAGTGTATATTAACATTGGTGCCGGTGCAGATACCCTGACCAAT GAACAGTGTACCCCGTATACCGTTCATTATGCCTATGATACAATGGCACTG GCAAAAGGTACAGGTAGCGCAGTTGTTAAACAAGGTGGTAAAACCTGGTT TTTCCTGACCGCAGATTATGCATTTGGTAAAGCACTGGAAAAGAATACCGC AGATGTTGTTAAAGCAAATGGTGGCAAAGTTCTGGGTGAAGTTCGTCATCC GCTGAGCGCAAGCGATTTTAGCAGCTTTCTGCTGCAGGCCCAGAGCAGCA AAGCCCAGATTCTGGGTTTAGCAAATGCCGGTGGTGATACCGTTAATGCAA TTAAAGCAGCCAAAGAATTTGGCATCACCAAAACCATGAAACTGGCAGCA CTGCTGATGTTTATTAACGATGTTCATGCATTAGGTCTGGAAACCACACAA GGTCTGGTTCTGACCGATAGCTGGTATTGGAATCGTGATCAGGCAAGCCGT CAGTGGGCACAGCGTTATTTTGCCAAAATGAAAAAGATGCCGAGCAGTCT GCAGGCAGCCGATTATAGCAGCGTTACCACCTATCTGAAAGCAGTTCAGG CAGCGGGTAGCACCGATAGCGATAAAGTTATGGCACAGCTGAAGAAAATG AAGATCGATGATTTTTACGCCAAAGGCTATATTCGTACCGATGGTAGCATG ATCCATGATATGTATCTGATGGAAGTTAAAAAGCCGAGCGAAAGCAAAGA ACCGTGGGATTATTACAAAGTTGTTGCAACCATTCCGGGTGAACAGGCATT TACCACAAAACAAGAAACCCGTTGTGCACTGTGGAAAAAGCTT (SEQ ID NO: 18)

[0232] Figures 30A-30D demonstrate new and updated results using Tt.2, EDC37, EDC24, and NovoS BEIBBPs, respectively, for intrinsic fluorescence-based quantification of BHB across various concentration ranges with a reference cuvette. Methods were as described for Figure 9. Measurements were taken on a Jasco Spectrofluorometer (295 nm excitation, 315-365 nm emission sweep). Error bars represent standard error of the mean between 3 experiments. The values on the plots correspond to the fitted dissociation constants obtained via nonlinear 4-parameter logistic regression and represent the relative affinities of the proteins for their cognate ligand.

[0233] Figures 31A-31D demonstrate results from a thermal shift assay using nano differential scanning fluorimetry (nanoDSF), which is a label-free technique for determining protein thermal stability. Experiments were conducted using thePrometheus NT.48 nanotemper differential scanning fluorimeter with a stress range of 20 °C to 95 °C at a ramp rate of 1 °C / min. Protein-ligand complexes were initiated in a 96-well plate with 150 pL total volume per well at a final concentration of 0.5 pM BHBBP. A single final concentration of 1 mM of BHB or structurally similar interferent from a library of compounds was introduced to the mixture. After 10 minutes shaking at 800 rpm, the samples were transferred to DSF grade standard capillaries and loaded inside the instrument. Fluorescence emissions at 330 nm and 350 nm were collected with UV excitation at 280 nm.

[0234] Tm or melting temperature is described as the midpoint of protein denaturation and is identified as the inflection point on the first derivative plot of the 350 / 330 nm fluorescence ratio.

[0235] Figures 31A-31D show nanoDSF results corresponding to proteins EDC24 (Figure 31A), EDC 10 (Figure 31B), BMA2936 (Figure 31C), and NovoS (Figure 31D), whereby the absolute Tmvalue for each protein-ligand mixture is plotted. All proteins demonstrate a maximal or close to maximal degree of thermal shift when mixed with either form of BHB (D / R or L / S enantiomers) or acetoacetate, the oxidized form of BHB. This great degree of thermal stabilization is suggestive of protein-ligand complex formation. Each bar represents the average of 4 measurements from independent mixtures (dots). These results underscore the high specificity of BHB BP - BHB complex formation.

[0236] Figure 32 shows the layout of wire sensor using NovoS BHBBP on gold working electrode (WE), and counter electrode (CE) with an Ag / AgCl reference electrode. The working electrode has NovoS immobilized using NTA self-assembled monolayer via nickel chelating interaction. Amine reactive phenazine ethosulfate is then conjugated to the NovoS binding protein.

[0237] Figure 33 shows the results of square wave voltammetry analyses of arPES modified NovoS protein on gold wire electrodes. After showing the steady state peak current in the absence of [3-hydroxybutyrate, the delta peak current was measured over time as the sensor response. The sensor signal increased immediately after the addition of 5 and 10 uM [3-hydroxybutyrate (final concentration). These results clearly indicate that BHB concentration can be monitored electrochemically using Novo-S BHBBP.

[0238] Figure 34 shows a calibration curve of |3-hydroxybutyrate using NovoS binding protein on gold wire electrode based on square wave voltammetry measurements.These results also demonstrate that BHB concentration can be monitored electrochemically using Novo-S BHBBP.

[0239] Advantages over alternative approaches

[0240] This invention presents the discovery of ketone binding proteins, BHBBPs, and their use in developing a CKM system for BHB detection. These proteins exhibit high specificity for BHB and undergo reversible conformational changes upon binding, which can be optically detected using fluorescence probes or electrochemically using redox probes. Unlike BHBDhs, BHBBPs do not require additional cofactors for measurement, resulting in a simpler sensor structure without need of specific membranes to retain soluble cofactors. Given their simple structure, the binding constant of BHBBPs to BHB can be tuned via mutational studies to optimally monitor levels of BHB from normal to DKA. Additionally, the thermophilic origin of Tt.2 BHBBP may provide structural stability at body temperature, making them ideal for in vivo monitoring.

[0241] Compared to NAD+-dependent dehydrogenase enzymes, BHBBPs offer greater versatility for developing various CKM devices using cutting-edge analytical technologies. This invention presents an electrochemical CKM sensing system that uses redox-probe-modified BHBBPs and an intermittent pulse amperometry (IPA) monitoring method for conformational changes. Additionally, a chemiresistor-type field-effect transistor (FET) based sensing principle, extended gate FET (EGFET) without the need for redox-probe modification, will be developed. The detection of BHB based on the conformational change of BHBBPs is not limited to electrochemical principles, as the modification of environmentally sensitive fluorescence probes can enable instant adoption of a fluorometric-based continuous monitoring system.

[0242] Many modifications and other embodiments of the inventions set forth herein will come to mind to one skilled in the art to which the inventions pertain having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the inventions are not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims.

[0243] Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation. Each embodiment disclosed herein is contemplated as being applicable to each of the other disclosed embodiments.All combinations and sub-combinations of the various elements described herein are within the scope of the embodiments.

[0244] List of cited references

[0245] [1] Kitabchi, A. et al., Hyperglycemic Crises in Adult Patients With Diabetes. Diabetes Care 32, 1335-1343 (2009).

[0246] [2] Dhatariya, K., Blood ketones: Measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. Rev. Diabet. Stud. 13, 217-225 (2016).

[0247] [3] Dhatariya, K. et al., Diabetic ketoacidosis. Nat. Rev. Dis. Primers 6, 1-20 (2020).

[0248] [4] Mitchell, G. et al., Medical aspects of ketone body metabolism. Clin. Invest. Med. 18, 193-216 (1995).

[0249] [5] Laffel, L., Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab. Res. Rev. 15, 412-426 (1999).

[0250] [6] Peters, A. et al., Diabetic Ketoacidosis With Canagliflozin, a Sodium Ghicose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes. Diabetes Care 39, 532-538 (2016).

[0251] [7] U.S. Food and Drug Administration (FDA), FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 1-4 (2015) (Announcement 19 May 2015, revised Dec 4, 2015).

[0252] [8] European Medicines Agency (EMA), EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. 1-3 (2016) (Accessed 25 June 2016).

[0253] [9] Rosenstock, J. and Ferrannini, E., Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with sglt2 inhibitors. Diabetes Care 38, 1638-1642 (2015).

[0254]

[0010] Wallace, T. and Matthews, D., Recent advances in the monitoring and management of diabetic ketoacidosis. QJM: An International Journal of Medicine 97, 773-780 (2004).

[0255]

[0011] Diabetes.co.uk., Ketone testing. Diabetes Digital Media (2019). https: / / www.diabetes.co.uk / diabetes_care / testing-for-ketones.html

[0256]

[0012] Pluddemann A. et al., Point-of-care blood test for ketones in patients with diabetes: primary care diagnostic technology update. Br. J. Gen. Pract. 61, 530-531 (2011).

[0257]

[0013] Batchelor, M. et al., Amperometric assay for the ketone body 3- hydroxybutyrate. Anal. Chim. Acta 221, 289-294 (1989).

[0258]

[0014] McNeil, C. et al., Amperometric biosensor for rapid measurement of 3- hydroxybutyrate in undiluted whole blood and plasma. Anal. Chim. Acta 237, 99-105 (1990).

[0259]

[0015] Martinez-Garcia, G. et al., An electrochemical enzyme biosensor for 3- hydroxybutyrate detection using screen-printed electrodes modified by reduced graphene oxide and thionine. Biosensors 7, 50 (2017).

[0260]

[0016] Mascini, M. et al., In-line determination of metabolites and milk components with electrochemical biosensors. Anal. Chim. Acta 213, 101-1 11 (1988).

[0261]

[0017] Palleschi, G. et al., Amperometric probe for 3 -hydroxybutyrate with immobilized 3 -hydroxy butyrate dehydrogenase. Anal. Chim. Acta 209, 223-230 (1988).

[0262]

[0018] Marrazza, G. et al., NADH electrochemical sensor for the enzymatic determination of L- and D-lactate and 3 -hydroxybutyrate using a flow injection analysis. Electroanalysis 6, 221-226 (1994).

[0263]

[0019] Uno, S. et al., Enzymatic method for determining ketone body ratio in arterial blood. Clin. Chem. 41, 1745-1750 (1995).

[0264]

[0020] Forrow, N. et al., Development of a commercial amperometric biosensor electrode for the ketone d-3-hydroxybutyrate. Biosens. Bioelectron. 20, 1617-1625 (2005).

[0265]

[0021] Li, G. et al., A new handheld biosensor for monitoring blood ketones. Sens. Actuators B Chem. 109, 285-290 (2005).

[0266]

[0022] Fang, L. et al. An electrochemical biosensor of the ketone 3-P-hydroxybutyrate for potential diabetic patient management. Sens. Actuators B Chem. 129, 818-825 (2008).

[0267]

[0023] Veerapandian, M. et al., Ruthenium dye sensitized graphene oxide electrode for on-farm rapid detection of beta-hydroxybutyrate. Sens. Actuators B Chem. 228, ISO- 184 (2016).

[0268]

[0024] Vojinovic, V. et al., Real-time bioprocess monitoring: part I: in situ sensors. Sens. Actuators B Chem. 114, 1083-1091 (2006).

[0269]

[0025] Lee, I. et al., Continuous glucose monitoring systems-current status and future perspectives of the flagship technologies in biosensor research. Biosens. Bioelectron. 181, 113054 (2021).

[0270]

[0026] Teymourian, H. et al., Microneedle-Based Detection of Ketone Bodies along with Glucose and Lactate: Toward Real-Time Continuous Interstitial Fluid Monitoring of Diabetic Ketosis and Ketoacidosis. Anal. Chem. 92, 2291 2300 (2020).

[0271]

[0027] Alva, S. et al., Feasibility of Continuous Ketone Monitoring in Subcutaneous Tissue using a Ketone Sensor. J. Diabetes Sci. Technol. 15, 768-774 (2021).

[0272]

[0028] Edwards, K., Periplasmic-binding protein-based biosensors and bioanalytical assay platforms: Advances, considerations, and strategies for optimal utility. Taianta 3, 100038 (2021).

[0273]

[0029] Rernandez-Lopez, R. et al., Transcription factor-based biosensors enlightened by the analyte. Front. Microbiol. 6, 648 (2015).

[0274]

[0030] Berntsson, R. et al., A structural classification of substrate-binding proteins. FEBS Lett. 584, 2606-2617 (2010).

[0275]

[0031] Marvin, J. et al., The rational design of allosteric interactions in a monomeric protein and its applications to the construction of biosensors. Pro. Natl. Acad. Sci. U.S.A. 94, 4366-4371 (1997).

[0276]

[0032] Tolosa, L. et al, Glucose sensor for low-cost lifetime-based sensing using a genetically engineered protein. Anal. Biochem. 267, 114-120 (1999).

[0277]

[0033] Salins, L. et al., A novel reagentless sensing system for measuring glucose based on the galactose / glucose-binding protein. Anal. Biochem. 294, 19-26 (2001).

[0278]

[0034] Benson, D. et al., Design of bioelectronic interfaces by exploiting hingebending motions in proteins. Science 293, 1641-1644 (2001).

[0279]

[0035] Judge, K. et al., Continuous glucose monitoring using a novel glucose / galactose binding protein: results of a 12-hour feasibility study with the Becton Dickinson glucose / galactose binding protein sensor. Diabetes Technol. Ther. 13, 309-317 (201 1).

[0280]

[0036] Santos-Cancel, M. et al., Rapid Two-Millisecond Interrogation of Electrochemical, Aptamer-Based Sensor Response Using Intermittent Pulse Amperometry. ACS Sens. 3, 1203-1209 (2018).

[0281]

[0037] Pellitero, M. et al., Critical review — Approaches for the electrochemical interrogation of DNA-based sensors: A critical review. J. Electrochem. Soc. 167, 037529 (2019).

[0282]

[0038] Amiss, T. et al., Engineering and rapid selection of a low-affinity glucose / galactose-binding protein for a glucose biosensor. Protein Sci. 16, 2350-2359 (2007).

[0283]

[0039] Sakaguchi-Mikami, A. et al., Engineering of Ligand Specificity of Periplasmic Binding Protein for Glucose Sensing. Biotechnol. Lett. 30, 1453-1460 (2008).

[0284]

[0040] Taneoka, A. et al., The Construction of a Glucose-Sensing Luciferase. Biosens. Bioelectron. 25, 76-81 (2009).

[0285]

[0041] Sakaguchi-Mikami, A. et aL, Construction of a novel glucose-sensing molecule based on a substrate-binding protein for intracellular sensing. Biotechnol. Bioeng. 108, 725-733 (2011).

[0286]

[0042] Pickup, J. et al., Fluorescence intensity- and lifetime-based glucose sensing using glucose / galactose-binding protein. J. Diabetes Sci. Technol. 7, 62-71 (2013)

[0287]

[0043] Joel, S. et al., Glucose recognition proteins for glucose sensing at physiological concentrations and temperatures. ACS Chem. Biol. 9, 1595-1602 (2014).

[0288]

[0044] Brown, S. et al., Minimally invasive technique for measuring transdermal glucose with a fluorescent biosensor. Anal. Bioanal. Chem. 410, 7249-7260 (2018).

[0289]

[0045] Sakaguchi, A. et al., SocA is a novel periplasmic binding protein for fructosyl amino acid. Biochem. Biophys. Res. Commun. 336, 1074-1080 (2005).

[0290]

[0046] Sakaguchi, A. et al., Novel fluorescent sensing system for a-fructosyl amino acids based on engineered fructosyl amino acid binding protein. Biosens. Bioelectron. 22, 1933-1938(2007).

[0291]

[0047] Sakaguchi, A. et al., Identification and functional analysis of fructosyl amino acid binding protein from gram-positive bacterium Arthrobacter sp. -Arthrobacter fructosyl amino acid binding protein-. J. Appl. Microbiol. 114, 1449-1456 (2013).

[0292]

[0048] Hatada, M. et al., Affinity sensor for haemoglobin Ale based on single-walled carbon nanotube field effect transistor and fructosyl amino acid binding protein. Biosens. Bioelectron. 129, 254-259 (2019).

[0293]

[0049] Takamatsu, S. et al., Continuous electrochemical monitoring of L-glutamine using redox-probe-modified L-glutamine-binding protein based on intermittent pulse amperometry. Sens. Actuators B Chem. 346, 130554 (2021).

[0294]

[0050] Yokus, M. et al., Wearable Multimodal Biosensor System for Continuous Monitoring of Sweat Metabolites. Biosens. Bioelectron. 153, 1 12038 (2020).

[0295]

[0051] Dieffenderfer, J. et al., Towards a Sweat-based Wireless and Wearable Electrochemical Sensor. 2016 IEEE SENSORS 1-3 (2016).

[0296]

[0052] Yokus, M. et al., Towards Wearable Electrochemical Lactate Sensing using Osmotic-Capillary Microfluidic Pumping. 2019 IEEE SENSORS 1-4 (2019).

[0297]

[0053] Pozdin, V. et al., Modular Design for Epidermal Temperature Sensing. 2017 IEEE SENSORS 1-3 (2017).

[0298]

[0054] Songkakul, T. et al., Towards a Long-Term Multi-Site Electrochemical Wound Monitoring System. 2019 IEEE SENSORS 1-4 (2019).

[0299]

[0055] Pozdin, V. et al., Low-Cost Flexible Inorganic Optical Devices for Flexible Sensors. 2017 IEEE SENSORS 1-3 (2017).

[0300]

[0056] Pozdin, V. et al., Strain Sensors on Thermoplastic Polyurethane Films for Lightweight Epidermal Sensing. 2017 IEEE SENSORS 1-3 (2017).

[0301]

[0057] Yokus, M. et al., Towards a Wearable Perspiration Sensor. 2017 IEEE SENSORS 1-3 (2017).

[0302]

[0058] U.S. Food and Drug Administration (FDA), Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use-Guidance for Industry and Food and Drug Administration Staff-. 15-20 (2020)

[0303]

[0059] Blackshear, P. and Alberti, K., Experimental Diabetic Ketoacidosis. Sequential changes of metabolic intermediates in blood, liver, cerebrospinal fluid and brain after acute insulin deprivation in the streptozotocin-diabetic rat. Biochem. J. 138, 107-117 (1974).

[0304]

[0060] Coskun, O. et al., Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and [3-cell damage in rat pancreas. Pharmacol. Res. 51. 117-123 (2005).

[0305]

[0061] Lam, T. et al., Bumetanide reduces cerebral edema formation in rats with diabetic ketoacidosis. Diabetes 54, 510-516 (2005).

[0306]

[0062] Glaser, N. et al., Acute and chronic neuroinflammation is triggered by diabetic ketoacidosis in a rat model. BMJ Open Diab. Res. Care 8, e001793 (2020).

[0307]

[0063] Celia, L. et al.. Single-walled carbon nanotube-based chemiresistive affinity biosensors for small molecules: Ultrasensitive glucose detection. J. Am. Chem. Soc. 132, 5024-5026 (2010).

[0308]

[0064] Das, B. et al., Single-walled carbon nanotubes chemiresistor aptasensors for small molecules: Picomolar level detection of adenosine triphosphate. Chem. Commun. 47, 3793-3795 (2011).

[0309]

[0065] Park, M. et al., Carbon nanotubes-based chemiresistive immunosensor for small molecules: Detection of nitroaromatic explosives. Biosens. Bioelectron. 26, 1297-1301 (2010).

[0310]

[0066] Rajesh, et al., High performance dendrimer functionalized single-walled carbon nanotubes field effect transistor biosensor for protein detection. Appl. Phys. Lett. 109, 1-6 (2016).

[0311]

[0067] Ramnani, P. et al.. Electronic detection of MicroRNA at attomolar level with high specificity. Anal. Chem. 85, 8061-8064 (2013).

Claims

WHAT IS CLAIMED IS:

1. A R-3-hydroxy butyrate binding protein (BHBBP) comprising a sequence having at least 70% sequence identity to any one of SEQ ID NOs: 1 -3 or 1 1 -14.

2. The BHBBP of claim 1, comprising a sequence having at least 80% sequence identity but less than 100% sequence identity to any one of SEQ ID NOs: 1-3 or 11-14.

3. The BHBBP of claim 1 or 2, further comprising a fluorescent probe bound thereto.

4. The BHBBP of claim 1 or 2. further comprising a redox probe bound thereto.

5. The BHBBP of claim 4, wherein the redox probe is selected from the group consisting of phenazine ethosulphate, an osmium complex, a ruthenium complex, ferrocene, methylene blue, and heme.

6. A recombinant plasmid comprising a promoter operably linked to a nucleotide sequence encoding the BHBBP of claim 1 or claim 2, and prepared by inserting the nucleotide sequence into an expression vector.

7. The recombinant plasmid of claim 6, wherein the nucleotide sequence is any one of SEQ ID NOs: 4-6 or 15-18.

8. The recombinant plasmid of claim 6 or 7, wherein the expression vector is a pET28a(+) vector, a pET30 vector, or a pET22b(+) vector.

9. A method of producing recombinant BHBBP, said method comprising: i) introducing the recombinant plasmid of any one of claims 6-8 into a host cell; and ii) expressing the BHBBP.

10. A method of determining the concentration of R-3-hydroxy butyrate (BHB) in a sample, the method comprising the steps of:i) contacting the sample with the BHBBP of any one of claims 1-3; ii) contacting the BHBBP with an excitation light; iii) measuring the intensity of light emitted from the BHBBP; and iv) determining the BHB concentration based on the measurement obtained in step hi).

11. The method of claim 10, wherein the excitation light has a wavelength of 250- 1000 nm.

12. The method of claim 11, wherein the excitation light has a wavelength of 280- 310 nm.

13. The method of any one of claims 10-12, wherein the light emitted has a wavelength of 200-1000 nm.

14. The method of claim 13, wherein the light emitted has a wavelength of 320- 340 nm.

15. The method of any one of claims 10-14, wherein the measurement is a continuous measurement.

16. The method of claim 15, wherein the measurement is performed for a period of time ranging from 30 seconds to 7 days.

17. The method of any one of claims 10-16, wherein the sample comprises a buffer.

18. The method of any one of claims 10-16, wherein the sample comprises whole blood, serum, interstitial fluid (ISF), sweat or saliva.

19. A method of determining the concentration of R-3-hydroxy butyrate (BHB) in a sample, the method comprising the steps of: i) contacting the sample with the BHBBP of claim 4 or 5;ii) applying an alternating potential to the sample, said alternating potential comprising a high potential and a low potential; iii) measuring a current in the sample while either the high potential or the low potential is applied; and iv) determining the BHB concentration based on the measurement obtained in step hi).

20. The method of claim 19, where the high potential is -0.3 to +0. 1 V.

21. The method of claim 20, wherein the high potential is -0.1 V.

22. The method of any one of claims 19-21, wherein the low potential is -0.4 - 0 V.

23. The method of claim 22, wherein the low potential is -0.2 V.

24. A binding protein immobilized electrode comprising the BHBBP of any one of claims 1 -6 immobilized on an electrode.

25. A biosensor for assaying BHB concentration comprising the BHBBP immobilized electrode of claim 24 as a working electrode.

26. A continuous ketone monitoring system, comprising: i) the BHBBP of any one of claims 1-5. the BHBBP electrode of claim 24. or the BHBBP sensor of claim 25; and ii) a) a light source and a light detection means, or b) a means for applying voltage across a sample, and a means for detecting current.

Citation Information

Patent Citations

  • Systems and methods for electrochemical ketone detection and measurement

    US20160327562A1

  • Methods and compositions for detecting beta-hydroxybutyrate in biological fluids

    US20210147900A1

  • Sensing devices based on microneedle arrays for sensing applications including ketone bodies monitoring

    US20220361776A1

  • Analyte sensors and sensing methods featuring dual detection of glucose and ketones

    US20230123384A1

  • Sensors for 3-hydroxybutyrate detection

    US20230123613A1